Kymriah gets speedy reviews in US and EU as Novartis looks to swiftly expand CAR-T indications
Equipped with data to directly compete with Gilead’s $GILD CAR-T, Novartis has secured promises of quick reviews of Kymriah for a second indication in both the United States and Europe.
The Swiss drugmaker $NVS started the day with news that the FDA has granted priority review to Kymriah in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for or relapse after autologous stem cell transplant. That’s something Yescarta goes after, and marks a new target for Kymriah after B-cell acute lymphoblastic leukemia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.